Evaluation of the Efficacy, Safety, and Tolerability of BHV-2100 and BHV-7000 in the Management of Pain in Healthy Male Subjects

The primary objective of the study is to evaluate the **effectiveness**, **safety**, and **tolerability** of BHV-2100 and BHV-7000 as a pain medication in healthy male participants. This is clinically relevant as it aims to determine the potential of these compounds to provide a new therapeutic option for managing pain, which is a common and often debilitating condition. The study does not specify any secondary objectives.

The clinical trial focuses on **pain** management and involves a study population consisting exclusively of male participants. The age range of the participants is categorized under code "3," which typically corresponds to a specific adult age group, although the exact age range is not specified. The trial does not include a vulnerable population, and the participants are expected to be in general good health, as no specific health conditions are mentioned. The total number of participants is not provided, as the sponsor has not disclosed this information. The selection criteria for the trial population, including any lifestyle considerations such as diet or physical activity, are not detailed in the available data. Additionally, the trial does not specify any principal inclusion or exclusion criteria, leaving the precise characteristics of the study population largely undefined.

The clinical trial is designed to evaluate the **efficacy**, safety, and tolerability of BHV-2100 and BHV-7000 as pain medications in healthy male participants. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial is expected to commence recruitment on September 1, 2024, and is estimated to conclude by December 31, 2024. The study employs a randomized, double-blind, controlled design to ensure unbiased results and to maintain the integrity of the data collected.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to receive either the investigational product or a control. Throughout the trial, participants will attend scheduled follow-up visits to monitor their response to the treatment and to assess any adverse effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected duration of participant involvement in the trial is contingent upon the study's timeline, with individual participation lasting until the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 1, 2024, with an estimated completion date of December 31, 2024. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis, adhering to the rigorous standards expected in a Phase 3 clinical trial. The study will utilize validated tools and instruments to ensure the accuracy and reliability of the efficacy assessments, although specific tools are not mentioned. The trial's design and execution will align with the objective of evaluating the therapeutic benefits of the investigational product, ensuring that the findings are scientifically robust and clinically relevant.